Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : ResAppDx receives regulatory approval in Indonesia

08/31/2021 | 06:52pm EDT

View printer-friendly version

Brisbane, Australia, 1 September 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce receipt of Indonesian regulatory approval for its smartphone-based acute respiratory disease diagnostic test, ResAppDx.

ResApp has partnered with Alodokter, the largest provider of telehealth services in Indonesia, to launch ResAppDx in Indonesia prior to 1 December 2021 (ref ASX announcement 4 August 2021).

CEO and Managing Director, Dr Tony Keating said: 'Obtaining regulatory approval in Indonesia is an important step in our partnership with Alodokter. With a population of over 270 million and a growing telehealth market, Indonesia represents an exciting opportunity for ResApp and with Alodokter we have an important partner that should see significant use of ResAppDx by doctors and their patients.'

###

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Disclaimer

ResApp Health Limited published this content on 01 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 August 2021 22:51:04 UTC.


© Publicnow 2021
All news about RESAPP HEALTH LIMITED
10/10RESAPP HEALTH : ReAapp Health Seeks US FDA Nod for Apnea Assessment Mobile App
MT
10/10RESAPP HEALTH : announces FDA 510(k) submission for SleepCheckRx
PU
10/10Resapp Announces FDA 510(K) Submission for Sleepcheckrx
CI
09/19RESAPP HEALTH : Recruits First Patients in India in COVID-19-Related Cough Sounds Study
MT
09/19RESAPP HEALTH : First patients recruited in COVID-19 clinical study in India
PU
09/19Resapp Health Limited Announces First Patients Recruited in Covid-19 Clinical Study in ..
CI
09/14RESAPP HEALTH : Gets Regulatory Nod for R&D Rebate; Shares Fall 6%
MT
09/13RESAPP HEALTH : receives Advanced and Overseas R&D finding
PU
09/13ResApp Health Limited Receives Advanced and Overseas R&D Finding
CI
09/01RESAPP HEALTH : Secures Indonesian Regulatory Approval for Diagnostic App
MT
More news
Financials
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -5,06 M -5,06 M
Net cash 2021 6,40 M 4,78 M 4,78 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 57,6 M 42,7 M 43,0 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 80,9%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RESAPP HEALTH LIMITED-21.18%43
SNAP INC.51.39%120 586
ANGI INC.-5.80%6 267
GRUBHUB INC.-19.36%5 591
PERFECT WORLD CO., LTD.-50.85%4 516
KAKAO GAMES CORP.54.57%4 473